The Division of Pediatric Nephrology at UPMC Children's Hospital of Pittsburgh provides a full range of services for the evaluation and management of children with simple or complex nephrologic or urologic disorders, including:

  • Complex and serious disorders resulting in end-stage renal disease requiring dialysis and/or transplantation
  • Electrolyte disturbances
  • Glomerulonephritis
  • Hematuria
  • Pediatric hypertension
  • Proteinuria
  • Urinary tract infections

The staff is well equipped to provide both acute and chronic management of various kidney problems, and consultative services to other departments within the hospital and to community physicians. Inpatient and outpatient consultations are available for children with electrolyte and acid-base disorders. The division works in a multidisciplinary fashion to provide the most advanced kidney replacement therapies in acutely ill children. Therapies include acute hemodialysis, hemofiltration/hemo-diafiltration (CVVH/CVVHD), the new Aquadex therapy, and acute peritoneal dialysis for patients weighing under 2kg. We perform specialized techniques for continuous kidney replacement therapy (CKRT) including circuit to circuit exchanges, tandem CKRT with therapeutic plasma exchange as well as tandem CKRT with therapeutic plasma exchange for patients receiving extracorporeal therapy. We offer multiple strategies for anticoagulation including heparin, citrate, argatroban and prostacyclin, allowing us to successfully dialyze critically ill patients with multiple co-morbidities.

Staff members work closely with urologic and pediatric surgeons to provide comprehensive management of patients.

Nephrology Research
The Division of Pediatric Nephrology at UPMC Children's Hospital of Pittsburgh is one of the leading programs in nation in both basic and clinical research. Our faculty is involved in a broad range of research activities which enhances both clinical care and medical education.

Nephrology Fellowship Program
The Division of Pediatric Nephrology offers a three-year ACGME-accredited fellowship program with two positions per year. The training program is funded with a prestigious NIH T32 training grant.  It offers outstanding opportunities for both clinical and research training.

Referral Requirements

Referrals are required from primary care physicians or other Children’s Hospital specialty services. Referrals for patients enrolled in managed care insurance plans also may require authorization from the insurance provider and primary care physician. All necessary referral and authorization forms must be received before the patient’s visit. For accurate provider numbers or more information, please call the office number listed.

The referring physician should supply:

  • All medical summaries
  • Radiologic studies, including films and reports
  • Biopsy materials (when available)


Clinical Studies

  • Nephrology

    UPMC Children's Hospital of Pittsburgh
    4401 Penn Avenue
    Floor 3
    Pittsburgh, PA 15224
  • Children's East

    4055 Monroeville Blvd.
    Building One
    Monroeville, PA 15146
  • Children's North

    2599 Wexford Bayne Rd.
    Sewickley, PA 15143
  • Children's South

    205 Millers Run Rd.
    Bridgeville, PA 15017
  • UPMC Children's Specialty Care Center Erie at Magee–Womens, UPMC Hamot

    Magee–Womens, UPMC Hamot
    118 East 2nd Street
    Erie, PA 16507
  • UPMC Children's Specialty Care Center Hermitage

    UPMC Outpatient Center
    449 N. Hermitage Road
    Hermitage, PA 16148
  • UPMC Children's Specialty Care Center Johnstown

    865 Eisenhower Blvd.
    Johnstown, PA 15904
  • UPMC Children's Specialty Care Center Washington

    Washington Hospital
    155 Wilson Ave.
    Washington, PA 15301
  • Chronic Kidney Disease & Hyperkalemia Treatment with Patiromer: The EMERALD Study – Phase II

    Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to

    Read more

    Chronic Kidney Disease & Hyperparathyroidism Treatment with Hectorol – Phase III

    Study to Assess the Safety and Efficacy of Hectorol® (doxercalciferol capsules) in Pediatric Patients with Chronic Kidney Disease Stages 3 and 4 with Secondary Hyperparathyroidism Not Yet on Dialysis

    Read more

    FSGS & the Effects of LDL Apheresis

    Effect of LDL-Apheresis on Cardiovascular and Renal Outcomes in Focal Segmental Glomerulosclerosis

    Read more

    FSGS and Identification of the APOL1 Genetic Mutation

    A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

    Read more

    FSGS Therapy Using Sparsentan – Phase III

    The Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis

    Read more

    FSGS Treatment with VX-147 – Phase IIa

    A 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX‐147 in Adults with APOL1-mediated Focal Segmental Glomerulosclerosis

    Read more

    Hyperoxaluria Treatment with DCR-PHXC – Phase II

    Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection in Patients with Primary Hyperoxaluria

    Read more

    Kidney Transplant Rejection Study Using Novel Blood Test

    Utilization of dd-cfDNA to Assess for Rejection

    Read more